atezolizumabbevacizumabatezolizumab-containingaspirinlow-dose aspirinHigh-grade serous ovarian cancerPROCEORTC-1508GCGPD-L1 blockadeplatinum-resistant ovarian cancer+1 more
…with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab (anti-VEGF), and low-dose aspirin in …